These authors contributed equally to this study.
Alteration of endocannabinoid system in human gliomas
Version of Record online: 23 JAN 2012
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry
Journal of Neurochemistry
Volume 120, Issue 5, pages 842–849, March 2012
How to Cite
Wu, X., Han, L., Zhang, X., Li, L., Jiang, C., Qiu, Y., Huang, R., Xie, B., Lin, Z., Ren, J. and Fu, J. (2012), Alteration of endocannabinoid system in human gliomas. Journal of Neurochemistry, 120: 842–849. doi: 10.1111/j.1471-4159.2011.07625.x
- Issue online: 10 FEB 2012
- Version of Record online: 23 JAN 2012
- Accepted manuscript online: 16 DEC 2011 10:44AM EST
- Received June 7, 2011; revised manuscript received August 26, 2011; accepted December 5, 2011.
Figure S1. Histological staining with H&E on normal brain tissue (a), non-tumor brain tissue control (b), low-grade glioma tissue (c) and high-grade glioma tissue (d).
Figure S2. The levels of anandamide (a), 2-AG (b), and OEA (c) in normal brain tissues (open bars) and non-tumor brain tissues (closed bars).
Figure S3. Immuno-histochemistry showed the increase of CB1 in human gliomas. The expression level of CB1 was detected with antibody against CB1 in non-tumor brain tissues (a), low-grade gliomas (b), and high-grade gliomas (c).
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|JNC_7625_sm_FigS1-S3.pdf||19321K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.